The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Translating bacteriophage-derived depolymerases into antibacterial therapeutics: Challenges and prospects
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Native or engineered phages equipped with polysaccharide depolymerases degrade EPS and expose embedded cells to antibiotics and immune factors.”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [210]
In the citing paper
“Reviews document strong biofilm-degrading activity against Gram-negative biofilms, including P. aeruginosa [209,210].”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [210]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Phages and their potential to modulate the microbiome and immunity
Federici, S., Nobs, S. P., & Elinav, E. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00532-4 · Cited by 222
Research works printed but not linked: 96
- Christaki, 2020, Antimicrobial resistance in bacteria: mechanisms, evolution, and persistence, J Mol Evol, 88, 26, 10.1007/s00239-019-09914-3 · DOI · Paper page
- Baker, 2018, Technologies to address antimicrobial resistance, Proc Natl Acad Sci U S A, 115, 12887, 10.1073/pnas.1717160115 · DOI · Paper page
- Mousavi, 2021, Bacteriophage as a novel therapeutic weapon for killing colistin-resistant multi-drug-resistant and extensively drug-resistant Gram-negative bacteria, Curr Microbiol, 78, 4023, 10.1007/s00284-021-02662-y · DOI
- Knecht, 2020, Diversity and function of phage encoded depolymerases, Front Microbiol, 10, 2949, 10.3389/fmicb.2019.02949 · DOI · Paper page
- Koskella, 2014, Bacteria-phage coevolution as a driver of ecological and evolutionary processes in microbial communities, FEMS Microbiol Rev, 38, 916, 10.1111/1574-6976.12072 · DOI · Paper page
- Abarquero, 2021, Study of exopolysaccharides from lactic acid bacteria and their industrial applications: a review, Int J Food Sci Technol, 57, 16, 10.1111/ijfs.15227 · DOI
- Hoiby, 2017, A short history of microbial biofilms and biofilm infections, APMIS, 125, 272, 10.1111/apm.12686 · DOI · Paper page
- Flemming, 2010, The biofilm matrix, Nat Rev Microbiol, 8, 623, 10.1038/nrmicro2415 · DOI · Paper page
- Labrie, 2010, Bacteriophage resistance mechanisms, Nat Rev Microbiol, 8, 317, 10.1038/nrmicro2315 · DOI · Paper page
- Oechslin, 2018, Resistance development to bacteriophages occurring during bacteriophage therapy, Viruses, 10, 351, 10.3390/v10070351 · DOI · Paper page
- Chen, 2022, Phage-derived depolymerase as an antibiotic adjuvant against multidrug-resistant Acinetobacter baumannii, Front Microbiol, 13
- Topka-Bielecka, 2021, Bacteriophage-derived depolymerases against bacterial biofilm, Antibiotics, 10, 175, 10.3390/antibiotics10020175 · DOI · Paper page
- Liston, 2018, Periplasmic depolymerase provides insight into ABC transporter-dependent secretion of bacterial capsular polysaccharides, Proc Natl Acad Sci U S A, 115, E4870, 10.1073/pnas.1801336115 · DOI
- Twort, 1915, An investigation on the nature of ultra-microscopic viruses, Lancet, 186, 1241, 10.1016/S0140-6736(01)20383-3 · DOI · Paper page
- d'Herelle, 1917, An invisible microbe that is antagonistic to the dysentery bacillus, C R Acad Sci, 165, 373
- Asheshov, 1924, Experimental studies on the bacteriophage, J Infect Dis, 34, 536, 10.1093/infdis/34.5.536 · doi:10.1093/infdis/34.5.536
- Sertic, 1929, Origine de la lysine d'une race du bacteriophage, Compt Rend Soc Biol, 100, 477
- Sertic, 1937, Sur la sensibilite d'une souche d'Escherichia coli au bactdriophage, en relation avec les caracteres antig6niques, Compt Rend Soc Biol, 126, 734
- Adams, 1956, An enzyme produced by a phage-host cell system: II. the properties of the polysaccharide depolymerase, Virology, 2, 719, 10.1016/0042-6822(56)90054-X · DOI
- Stirm, 1971, Bacteriophage particles with endo-glycosidase activity, J Virol, 8, 343, 10.1128/jvi.8.3.343-346.1971 · doi:10.1128/jvi.8.3.343-346.1971
- Steinbacher, 1996, Crystal structure of phage P22 tailspike protein complexed with Salmonella sp. O-antigen receptors, Proc Natl Acad Sci U S A, 93, 10584, 10.1073/pnas.93.20.10584 · DOI · Paper page
- Latka, 2019, Modeling the architecture of depolymerase-containing receptor binding proteins in Klebsiella phages, Front Microbiol, 10, 2649, 10.3389/fmicb.2019.02649 · DOI
- Clarke, 2000, Cloning, expression, and purification of the K5 capsular polysaccharide lyase (KflA) from coliphage K5A: evidence for two distinct K5 lyase enzymes, J Bacteriol, 182, 3761, 10.1128/JB.182.13.3761-3766.2000 · doi:10.1128/jb.182.13.3761-3766.2000
- Leiman, 2008, Evolution of a new enzyme activity from the same motif fold, Mol Microbiol, 69, 287, 10.1111/j.1365-2958.2008.06241.x · DOI
- Barbirz, 2008, Crystal structure of Escherichia coli phage HK620 tailspike: podoviral tailspike endoglycosidase modules are evolutionarily related, Mol Microbiol, 69, 303, 10.1111/j.1365-2958.2008.06311.x · DOI
- Hughes, 1998, Bacteriophage and associated polysaccharide depolymerases—novel tools for study of bacterial biofilms, J Appl Microbiol, 85, 583, 10.1046/j.1365-2672.1998.853541.x · DOI · Paper page
- Mushtaq, 2004, Prevention and cure of systemic Escherichia coli K1 infection by modification of the bacterial phenotype, Antimicrob Agents Chemother, 48, 1503, 10.1128/AAC.48.5.1503-1508.2004 · DOI
- Waseh, 2010, Orally administered P22 phage tailspike protein reduces salmonella colonization in chickens: prospects of a novel therapy against bacterial infections, PLoS One, 5, 10.1371/journal.pone.0013904 · DOI
- Bansal, 2014, Depolymerase improves gentamicin efficacy during Klebsiella pneumoniae induced murine infection, BMC Infect Dis, 14, 456, 10.1186/1471-2334-14-456 · DOI
- Shahed-Al-Mahmud, 2021, Phage phiAB6-borne depolymerase combats Acinetobacter baumannii biofilm formation and infection, Antibiotics, 10, 279, 10.3390/antibiotics10030279 · DOI
- Pan, 2015, Identification of capsular types in carbapenem-resistant Klebsiella pneumoniae strains by wzc sequencing and implications for capsule depolymerase treatment, Antimicrob Agents Chemother, 59, 1038, 10.1128/AAC.03560-14 · DOI
- Mostowy, 2018, Diversity-generating machines: genetics of bacterial sugar-coating, Trends Microbiol, 26, 1008, 10.1016/j.tim.2018.06.006 · DOI
- Pires, 2016, Bacteriophage-encoded depolymerases: their diversity and biotechnological applications, Appl Microbiol Biotechnol, 100, 2141, 10.1007/s00253-015-7247-0 · DOI · Paper page
- Drulis-Kawa, 2015, Bacteriophages and phage-derived proteins—application approaches, Curr Med Chem, 22, 1757, 10.2174/0929867322666150209152851 · DOI · Paper page
- Nobrega, 2018, Targeting mechanisms of tailed bacteriophages, Nat Rev Microbiol, 16, 760, 10.1038/s41579-018-0070-8 · DOI · Paper page
- Squeglia, 2020, Structural and functional studies of a Klebsiella phage capsule depolymerase tailspike: mechanistic insights into capsular degradation, Structure, 28, 613, 10.1016/j.str.2020.04.015 · DOI
- Latka, 2017, Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate barriers during the infection process, Appl Microbiol Biotechnol, 101, 3103, 10.1007/s00253-017-8224-6 · DOI · Paper page
- Latka, 2021, Engineering the modular receptor-binding proteins of Klebsiella phages switches their capsule serotype specificity, mBio, 12, 10.1128/mBio.00455-21 · DOI
- Yan, 2014, Bacteriophage polysaccharide depolymerases and biomedical applications, BioDrugs, 28, 265, 10.1007/s40259-013-0081-y · DOI · Paper page
- Patro, 2020, A unified platform to distinguish Klebsiella species K- and O-antigen types, model antigen structures and identify hypervirulent strains, Sci Rep, 10, 10.1038/s41598-020-73360-1 · DOI
- Oliveira, 2022, Exploiting phage-derived carbohydrate depolymerases for combating infectious diseases, Trends Microbiol, 30, 707, 10.1016/j.tim.2022.05.002 · doi:10.1016/j.tim.2022.05.002
- Reuter, 2020, Approaches to optimize therapeutic bacteriophage and bacteriophage-derived products to combat bacterial infections, Virus Gene, 56, 136, 10.1007/s11262-020-01735-7 · DOI
- Drulis-Kawa, 2012, Learning from bacteriophages—advantages and limitations of phage and phage-encoded protein applications, Curr Protein Pept Sci, 13, 699, 10.2174/138920312804871193 · DOI · Paper page
- Li, 2017, Antibiofilm agents: a new perspective for antimicrobial strategy, J Microbiol, 55, 753, 10.1007/s12275-017-7274-x · DOI · Paper page
- Taraszkiewicz, 2013, Innovative strategies to overcome biofilm resistance, BioMed Res Int, 2013, 10.1155/2013/150653 · DOI · Paper page
- Limoli, 2015, Bacterial extracellular polysaccharides in biofilm formation and function, Microbiol Spectr, 3, 10, 10.1128/microbiolspec.MB-0011-2014 · DOI · Paper page
- Hernandez-Morales, 2018, Genomic and biochemical characterization of Acinetobacter podophage Petty reveals a novel lysis mechanism and tail-associated depolymerase activity, J Virol, 92, 10.1128/JVI.01064-17 · DOI
- Gutiérrez, 2012, Genomic characterization of two Staphylococcus epidermidis bacteriophages with anti-biofilm potential, BMC Genom, 13, 228, 10.1186/1471-2164-13-228 · DOI
- Gutiérrez, 2015, Role of the pre-neck appendage protein (Dpo7) from phage vB_SepiS-phiIPLA7 as an anti-biofilm agent in Staphylococcal species, Front Microbiol, 6, 1315, 10.3389/fmicb.2015.01315 · DOI
- Olsen, 2018, Synergistic removal of static and dynamic Staphylococcus aureus biofilms by combined treatment with a bacteriophage endolysin and a polysaccharide depolymerase, Viruses, 10, 438, 10.3390/v10080438 · DOI
- Chai, 2014, Application of bacteriophage-borne enzyme combined with chlorine dioxide on controlling bacterial biofilm, LWT--Food Sci Technol, 59, 1159, 10.1016/j.lwt.2014.06.033 · doi:10.1016/j.lwt.2014.06.033
- Oliveira, 2017, Synergistic antimicrobial interaction between honey and phage against Escherichia coli biofilms, Front Microbiol, 8, 2407, 10.3389/fmicb.2017.02407 · DOI
- Tait, 2002, The efficacy of bacteriophage as a method of biofilm eradication, Biofouling, 18, 305, 10.1080/0892701021000034418 · DOI
- Lu, 2007, Dispersing biofilms with engineered enzymatic bacteriophage, Proc Natl Acad Sci U S A, 104, 11197, 10.1073/pnas.0704624104 · DOI · Paper page
- Projan, 2004, Phage-inspired antibiotics?., Nat Biotechnol, 22, 167, 10.1038/nbt0204-167 · DOI
- Pires, 2017, Phage therapy as an alternative or complementary strategy to prevent and control biofilm-related infections, Curr Opin Microbiol, 39, 48, 10.1016/j.mib.2017.09.004 · DOI · Paper page
- Hughes, 1998, Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase, Microbiology (Read), 144, 3039, 10.1099/00221287-144-11-3039 · DOI · Paper page
- Hanlon, 2001, Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms, Appl Environ Microbiol, 67, 2746, 10.1128/AEM.67.6.2746-2753.2001 · DOI · Paper page
- Bansal, 2015, Aeromonas punctata derived depolymerase improves susceptibility of Klebsiella pneumoniae biofilm to gentamicin, BMC Microbiol, 15, 119, 10.1186/s12866-015-0455-z · DOI
- Wu, 2019, A novel polysaccharide depolymerase encoded by the phage SH-KP152226 confers specific activity against multidrug-resistant Klebsiella pneumoniae via biofilm degradation, Front Microbiol, 10, 2768, 10.3389/fmicb.2019.02768 · DOI · Paper page
- Majkowska-Skrobek, 2018, Phage-borne depolymerases decrease Klebsiella pneumoniae resistance to innate defense mechanisms, Front Microbiol, 9, 2517, 10.3389/fmicb.2018.02517 · DOI
- Oliveira, 2020, A tailspike with exopolysaccharide depolymerase activity from a new Providencia stuartii phage makes multidrug-resistant bacteria susceptible to serum-mediated killing, Appl Environ Microbiol, 86, 10.1128/AEM.00073-20 · DOI
- Abdelkader, 2022, The specific capsule depolymerase of phage PMK34 sensitizes Acinetobacter baumannii to serum killing, Antibiotics, 11, 677, 10.3390/antibiotics11050677 · DOI
- Oliveira, 2019, K2 Capsule depolymerase is highly stable, is refractory to resistance, and protects larvae and mice from Acinetobacter baumannii sepsis, Appl Environ Microbiol, 85, 10.1128/AEM.00934-19 · DOI
- Smug, 2022, PhREEPred: phage resistance emergence prediction web tool to foresee encapsulated bacterial escape from phage cocktail treatment, J Mol Biol, 434, 10.1016/j.jmb.2022.167670 · doi:10.1016/j.jmb.2022.167670
- Majkowska-Skrobek, 2021, The evolutionary trade-offs in phage-resistant Klebsiella pneumoniae entail cross-phage sensitization and loss of multidrug resistance, Environ Microbiol, 23, 7723, 10.1111/1462-2920.15476 · DOI
- Danis-Wlodarczyk, 2021, Treating bacterial infections with bacteriophage-based enzybiotics: in vitro, in vivo and clinical application, Antibiotics, 10, 1497, 10.3390/antibiotics10121497 · DOI
- Lin, 2014, Isolation of a bacteriophage and its depolymerase specific for K1 capsule of Klebsiella pneumoniae: implication in typing and treatment, J Infect Dis, 210, 1734, 10.1093/infdis/jiu332 · DOI · Paper page
- Volozhantsev, 2022, Comparison of the therapeutic potential of bacteriophage KpV74 and phage-derived depolymerase (beta-glucosidase) against Klebsiella pneumoniae capsular type K2, Virus Res, 322, 10.1016/j.virusres.2022.198951 · DOI
- Li, 2022, Identification of a phage-derived depolymerase specific for KL47 capsule of Klebsiella pneumoniae and its therapeutic potential in mice, Virol Sin, 37, 538, 10.1016/j.virs.2022.04.005 · DOI
- Wang, 2019, Protective and therapeutic application of the depolymerase derived from a novel KN1 genotype of Klebsiella pneumoniae bacteriophage in mice, Res Microbiol, 170, 156, 10.1016/j.resmic.2019.01.003 · DOI
- Majkowska-Skrobek, 2016, Capsule-targeting depolymerase, derived from Klebsiella KP36 phage, as a tool for the development of anti-virulent strategy, Viruses, 8, 324, 10.3390/v8120324 · DOI
- Volozhantsev, 2020, Characterization and therapeutic potential of bacteriophage-encoded polysaccharide depolymerases with beta galactosidase activity against Klebsiella pneumoniae K57 capsular type, Antibiotics, 9, 732, 10.3390/antibiotics9110732 · doi:10.3390/antibiotics9110732
- Gorodnichev, 2021, Novel Klebsiella pneumoniae K23-specific bacteriophages from different families: similarity of depolymerases and their therapeutic potential, Front Microbiol, 12, 10.3389/fmicb.2021.669618 · doi:10.3389/fmicb.2021.669618
- Liu, 2019, The capsule depolymerase Dpo48 rescues Galleria mellonella and mice from Acinetobacter baumannii systemic infections, Front Microbiol, 10, 545, 10.3389/fmicb.2019.00545 · doi:10.3389/fmicb.2019.00545
- Wang, 2020, Identification of a novel Acinetobacter baumannii phage-derived depolymerase and its therapeutic application in mice, Front Microbiol, 11, 1407, 10.3389/fmicb.2020.01407 · doi:10.3389/fmicb.2020.01407
- Mushtaq, 2005, Treatment of experimental Escherichia coli infection with recombinant bacteriophage-derived capsule depolymerase, J Antimicrob Chemother, 56, 160, 10.1093/jac/dki177 · DOI
- Lin, 2017, Therapeutic application of phage capsule depolymerases against K1, K5, and K30 capsulated E. coli in mice, Front Microbiol, 8, 2257, 10.3389/fmicb.2017.02257 · doi:10.3389/fmicb.2017.02257
- Lin, 2018, Antibiotic therapy using phage depolymerases: robustness across a range of conditions, Viruses, 10, 622, 10.3390/v10110622 · doi:10.3390/v10110622
- Chen, 2020, A novel tail-associated O91-specific polysaccharide depolymerase from a podophage reveals lytic efficacy of Shiga toxin-producing Escherichia coli, Appl Environ Microbiol, 86, 10.1128/AEM.00145-20 · DOI
- Olszak, 2017, The O-specific polysaccharide lyase from the phage LKA1 tailspike reduces Pseudomonas virulence, Sci Rep, 7, 10.1038/s41598-017-16411-4 · DOI
- Sumrall, 2021, An enzybiotic regimen for the treatment of methicillin-resistant Staphylococcus aureus orthopaedic device-related infection, Antibiotics, 10, 1186, 10.3390/antibiotics10101186 · DOI
- M Campos, 2020, Global priority pathogens: virulence, antimicrobial resistance and prospective treatment options, Future Microbiol, 15, 649, 10.2217/fmb-2019-0333 · DOI
- Ma, 2019, Considerations and caveats in combating ESKAPE pathogens against nosocomial infections, Adv Sci, 7
- Ryan, 2011, Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy, J Pharm Pharmacol, 63, 1253, 10.1111/j.2042-7158.2011.01324.x · DOI · Paper page
- Liu, 2019, Identification and characterization of capsule depolymerase Dpo48 from Acinetobacter baumannii phage IME200, PeerJ, 7
- Kassa, 2012, Thermal treatment of the bacteriophage lysate of Klebsiella pneumoniae B5055 as a step for the purification of capsular depolymerase enzyme, J Virol Methods, 179, 135, 10.1016/j.jviromet.2011.10.011 · DOI
- Montanari, 2017, Hyaluronan-cholesterol nanohydrogels: characterisation and effectiveness in carrying alginate lyase, N Biotech, 37, 80, 10.1016/j.nbt.2016.08.004 · DOI
- Dunstan, 2021, Mechanistic insights into the capsule-targeting depolymerase from a Klebsiella pneumoniae bacteriophage, Microbiol Spectr, 9, 10.1128/Spectrum.01023-21 · DOI
- Libertucci, 2019, The role of the microbiota in infectious diseases, Nat Microbiol, 4, 35, 10.1038/s41564-018-0278-4 · DOI · Paper page
- Gutierrez, 2018, Are phage lytic proteins the secret weapon to kill Staphylococcus aureus?., mBio, 9, 10.1128/mBio.01923-17 · DOI
- 2008, Structural Genomics Consortium, China Structural Genomics Consortium, Northeast Structural Genomics Consortium, Graslund S, Nordlund P, Weigelt J, et al. Protein production and purification, Nat Methods, 5, 135
- Klimyuk, 2014, Production of recombinant antigens and antibodies in Nicotiana benthamiana using 'magnifection' technology: GMP-compliant facilities for small- and large-scale manufacturing, Curr Top Microbiol Immunol, 375, 127
- Frokjaer, 2005, Protein drug stability: a formulation challenge, Nat Rev Drug Discov, 4, 298, 10.1038/nrd1695 · DOI · Paper page
- Cornforth, 2018, Pseudomonas aeruginosa transcriptome during human infection, Proc Natl Acad Sci U S A, 115, E5125, 10.1073/pnas.1717525115 · DOI · Paper page
- Bjarnsholt, 2022, The importance of understanding the infectious microenvironment, Lancet Infect Dis, 22, e88, 10.1016/S1473-3099(21)00122-5 · DOI · Paper page
Cited by
Elbehiry, A., Marzouk, E., Edrees, H. M., Ibrahem, M., Alzahrani, S., Anagreyyah, S., Abualola, H., Alghamdi, A., Alzahrani, A., Jaber, M., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14010109 · Cited by 34
Metadata
- Authors
- Wang, H., Liu, Y., Bai, C., & Leung, S. S. Y.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2024-01
- Volume
- 14
- Issue
- 1
- Pages
- 155-169
- ISSN
- 2211-3835
- Cited by
- 97
- References
- 2
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Research Grants Council, University Grants Committee (14112921)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.